Is Viking Therapeutics Stock Really Going to $125?
Most veteran investors can attest that, although they're also often a complete bust, every now and then a biopharma stock dishes out a windfall gain.
That's what the analyst community seems to expect from Viking Therapeutics (NASDAQ: VKTX) in the foreseeable future. The stock's current consensus price target of $92.94 is more than 200% above the ticker's present price, while one analyst -- BTIG's Justin Zelin -- says this stock's worth $125. That's more than 300% above its current value.
The question is, what do so many stock-picking pros see in this extremely unprofitable pharmaceutical start-up?
Source Fool.com
Viking Therapeutics Inc Aktie
29,90 €
-0,66 %
